



TFW

1655

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Crea  
Title: Method of Treating Diabetes Type II  
Docket No.: CREA-001US  
Serial No.: 10/564,924  
Filed: January 17, 2006  
Due Date: N/A  
Examiner: Michele C. Flood  
Group Art Unit: 1655

**MS Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ This transmittal document.
- ☒ Information Disclosure Statement (2 pg.), Form 1449 (1 pg.), and copies of 10 cited documents.
- ☒ Authorization to charge Deposit Account Number 50-3956 in the amount of \$0 to cover the fee for consideration of Information Disclosure Statement under 97( c) PTO - 2038 Form.

Customer Number: 51951

By Barbara J. Luther  
Barbara J. Luther  
Reg. No. 33,954

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 21st day of November, 2006.

Sharyn Conway, Paralegal  
Name

Sharyn Conway  
Signature

(GENERAL)

S/N 10/564,924



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Crea  
Serial No.: 10/564,924  
Filed: January 17, 2006  
Title: Method of Treating Diabetes Type II

Examiner: Michele C. Flood  
Group Art Unit: 1655  
Docket: CREA-001US

---

**INFORMATION DISCLOSURE STATEMENT**

Box Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Examiner:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. This paper does not attest that a search was conducted or that the references cited therein are prior art. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included no fee. Please charge any additional fees or credit any overpayment to Deposit Account No. 50-3956. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided,

**INFORMATION DISCLOSURE STATEMENT**

Serial No :10/564,924

Filing Date: January 17, 2006

Title: Method of Treating Diabetes Type II

Page 2

Dkt: CREA-001US


Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

By their Representatives,


Date November 21, 2006  
The Luther Law Firm, PLC  
10575 N. 114<sup>th</sup> St., Ste. 103  
Scottsdale, AZ 85259  
480-344-7745


By



Barbara J. Luther  
Reg. No. 33,954


CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 21st day of November, 2006.

  
Name

  
Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/564,924
Filing Date	January 17, 2006
First Named Inventor	CREA
Art Unit	1655
Examiner Name	Michele C. Flood

Attorney Docket No: CREA-001US

Sheet 1 of 1

## US PATENT DOCUMENTS

Examiner Initial *	Cite No	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date if Appropriate
		US-6165475	12/26/2000	Crea, Roberto et al.	01/26/2000
		US-6197308	03/06/2001	Crea, Roberto et al.	07/22/1999
		US-6416808	07/09/2002	Crea, Roberto	08/31/2001

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
---------------------	---------	---------------------	------------------	---	----------------

## OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BONANOME, A , et al., "Evidence of postprandial absorption of olive oil phenols in humans", <i>Nutr Metab Cardiovasc Dis</i> 10, (2000),111-20	
		CARUSO, DONATELLA , et al., "Urinary Excretion of olive oil phenols", <i>Metabolism</i> 12 (Dec), (2001),1426-28	
		D'ANGELO, STEFANIA , et al., "Pharmacokinetics and metaoblism of hydroxytyrosol", <i>Drug Metabolism and Disposition</i> 29(11), (2001),1492-98	
		DE LA PUERTA, ROCIO , et al., "Effects of virgin olive oil phenolics on scavenging or reactive nitrogen species and upon nitregeric neurotransmission", <i>Life Sci</i> 69, (2001),1213-22	
		DE LA PUERTA, ROCIO , et al., "Effects of virgin olive oli phenolics on scavenging", <i>Life Sci</i> 69, (2001),1213-22	
		TUCK, KELLIE L., et al., "The in vivo fate of hydroxytyrosol and tyrosol", <i>J Nutr</i> 131, (2001),1993-96	
		VISIOLI, FRANCESCO , et al., "Antiatherogenic components of Olive oil", <i>Current Atherosclerosis Reports</i> 3, (2001),64-67	
		VISIOLI, FRANCESCO , "Biological Properties of Olive Oil Phytochemicals", <i>Crit. Rev. Food Sci. Nutri.</i> 42(3), (2002),209-21	
		VISIOLI, FRANCESCO , et al., "Olive oils rich in natural catecholic phenols...", <i>Biochem Biophys Res Comm</i> 278, (2000),797-99	
		VISIOLI, FRANCESCO , et al., "Olive phenol hydroxytyrosol prevents apssive smoking stress", <i>Circulation</i> 102, (2000),2169-71	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached